AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +55

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

📊 AbbVie presents new clinical data at EHA 2026 covering six oral presentations across multiple blood cancer indications.

💉 EPCORE FL-1 trial subgroup analysis shows epcoritamab + lenalidomide/rituximab achieves 96.5% ORR in low-risk follicular lymphoma vs 84.8% for comparator.

📈 EPCORE DLBCL-1 results show epcoritamab monotherapy improves PFS vs chemoimmunotherapy (HR 0.74) with 30% vs 13% 24-month PFS.

🧬 CLL14 trial final results confirm venetoclax-obinutuzumab efficacy in previously untreated chronic lymphocytic leukemia patients.

🔬 REVIVE study presents real-world management practices for venetoclax-based therapy in newly diagnosed AML patients unfit for intensive chemotherapy.

🧪 Etentamig (ABBV-383) data presented for relapsed/refractory multiple myeloma with prior BCMA exposure and amyloidosis.

🩺 Pivekimab sunirine-pvzy efficacy data shown in blastic plasmacytoid dendritic cell neoplasm with skin involvement.

🤝 EPKINLY and VENCLEXTA are approved therapies being investigated for additional uses; etentamig and pivekimab remain investigational.

⚠️ Epcoritamab arm reported higher rates of grade 3-4 infections (30% vs 12%) and COVID-19 (36% vs 11%) in DLBCL trial.

📅 Full abstracts available via PR Newswire link; presentations held June 8, 2026 at EHA Congress in Stockholm.

Bullish Signals
  • EPCORE FL-1 subgroup analysis shows numerically higher overall response rates with epcoritamab + lenalidomide/rituximab across risk groups (96.5% vs 84.8% in low-risk).
  • EPCORE DLBCL-1 demonstrates statistically significant PFS improvement for epcoritamab monotherapy vs chemoimmunotherapy (HR 0.74; p=0.0059).
  • CLL14 trial final results support venetoclax-obinutuzumab as effective regimen in previously untreated CLL patients.
  • Real-world REVIVE study provides practical insights into venetoclax-based therapy management for AML in chemotherapy-unfit patients.
  • Etentamig shows promise in relapsed/refractory multiple myeloma with prior BCMA exposure, including triple-class resistance.
  • Pivekimab sunirine-pvzy demonstrates activity in rare BPDCN with skin involvement, supporting first-line use potential.
  • Long-term follow-up from EPCORE NHL-1 trial confirms sustained remissions beyond 4 years with epcoritamab monotherapy.
  • EPCORE FL-1 data supports improved or preserved health-related quality of life in patients with high symptom burden.
Risk Factors
  • In EPCORE DLBCL-1, epcoritamab arm reported higher rates of grade 3-4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%).
  • Grade 5 treatment-emergent adverse events occurred in 17% of epcoritamab patients vs 6% in comparator, largely due to severe COVID-19 cases.
  • EPCORE DLBCL-1 did not demonstrate statistically significant improvement in overall survival (HR 0.96; p=0.28).
  • Etentamig and pivekimab sunirine-pvzy remain investigational with no EU approval as of June 2026.
  • EPCORE FL-1 subgroup analysis noted lower ORR in high-risk FLIPI patients (93.0% vs 72.6%) compared to low-risk counterparts.
Full Analysis
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, acute myeloid leukemia, and amyloidosis. Key investigational compounds featured include etentamig (ABBV-383), EPKINLY (epcoritamab-bysp), VENCLEXTA (venetoclax), and DECNUPAZ (pivekimab sunirine-pvzy). Data from the EPCORE FL-1 trial demonstrated that epcoritamab combined with lenalidomide and rituximab achieved higher overall response rates in follicular lymphoma subgroups compared to standard therapy, with 96.5% response in low-risk patients versus 84.8%. In relapsed large B-cell lymphoma, epcoritamab monotherapy showed a statistically significant improvement in progression-free survival versus chemoimmunotherapy, with a hazard ratio of 0.74 and 24-month PFS of 30% compared to 13%. Additional studies presented include final results from the CLL14 trial showing efficacy of venetoclax-obinutuzumab in previously untreated chronic lymphocytic leukemia, real-world data from the REVIVE study on venetoclax-based therapy for AML, and early-phase data for etentamig in multiple myeloma and amyloidosis. The company emphasized its commitment to advancing innovative solutions to address challenges in treating blood cancers.